Pharsight

Neos Theraps Inc patents expiration

1. Adzenys Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9017731 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(8 years from now)

US9265737 NEOS THERAPS INC Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
Jun, 2032

(8 years from now)

US8709491 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(8 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 15 September, 2017

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

ADZENYS ER family patents

Family Patents

2. Cotempla Xr-odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8840924 NEOS THERAPS INC Compositions and methods of making rapidly dissolving ionically masked formulations
Jun, 2026

(2 years from now)

US9089496 NEOS THERAPS INC Compositions comprising methylphenidate complexed with ion-exchange resin particles
Jun, 2032

(8 years from now)

US9072680 NEOS THERAPS INC Compositions comprising methylphenidate complexed with ion-exchange resin particles
Jun, 2032

(8 years from now)

US11166947 NEOS THERAPS INC Effective dosing of a child for the treatment of ADHD with methylphenidate
Jan, 2038

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 19, 2020

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

How can I launch a generic of COTEMPLA XR-ODT before it's drug patent expiration?
More Information on Dosage

COTEMPLA XR-ODT family patents

Family Patents